Page last updated: 2024-11-05

rebemide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

rebemide: insect repellent; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID15542
CHEBI ID180965
SCHEMBL ID72112
MeSH IDM0065844

Synonyms (44)

Synonym
unii-3y74433zxi
4-09-00-00728 (beilstein handbook reference)
3y74433zxi ,
CHEBI:180965
nsc 16060
r 2 (van)
ai3-01197
einecs 216-912-9
brn 1909505
rebemide
benzoic acid n,n-diethylamide
1696-17-9
r 2 (insect repellant)
r 2
nsc-16060
benzoic acid diethylamide
rebemid
r 2 (insect repellent)
n,n-diethylbenzamide ,
r2
benzamide,n-diethyl-
nsc16060
benzoyldiethylamine
benzamide, n,n-diethyl-
inchi=1/c11h15no/c1-3-12(4-2)11(13)10-8-6-5-7-9-10/h5-9h,3-4h2,1-2h
REP ,
AKOS002984097
A811125
n,n-diethyl-benzamide
FT-0629468
SCHEMBL72112
n,n-diethylbenzamide [who-dd]
n,n-diethyl benzamide
n,n diethylbenzamide
n,n-diethyl -benzamide
DTXSID0051784
4-hydroxybenzoicacidn-amylester
n,n-n,n-diethybenzamide
mfcd00026726
D5123
A51047
Q27258203
AS-57367
SY234623
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzamides
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (20.00)18.7374
1990's1 (20.00)18.2507
2000's0 (0.00)29.6817
2010's3 (60.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (14.29%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (85.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]